Company intelligence / Profile preview

Vitatex

Stony Brook, New York, United States

Ownership: Private
Development stage: Other

Overview

Vitatex developed and validated a platform technology for enriching and analyzing invasive circulating tumor cells (iCTCs) from standard patient blood samples. Their CAM-based Vita-Assay enables early detection of metastatic potential, ex vivo drug-sensitivity testing, and companion diagnostics. The approach was validated in multiple cancer types and received $7M+ NCI funding. Clinical results support high-positive predictive value for cancer risk stratification, notably in ovarian cancer (PPV >97% for high-risk patients)

Therapeutic areas: OncologyOther
Modalities: Monoclonal antibodyCell-based assayDiagnostic assayPlatform technology for rare cell enrichment
Industry: Biotech

Partnerships

LineaRx (acquirer)The Research Foundation for The State University of New York (licensed IP)

Beyond the preview

Go deeper on Vitatex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitatex.

Explore the full profile